Connect and Catalyse Medicines and Healthcare the Global perspective (+10 years) Zahid Latif
% GDP spent on health OECD countries spent nearly $3.5trn in 2005 ($4.6 trillion in 2008) on healthcare services with over $1.8trn being spent by the US alone and the UK spending some $144bn. Healthcare bill for the OECD countries projected at $10trn per year by 2020, with the US spending some 21% of its GDP and the rest of the OECD countries spending an average of 16%.
The share of GDP allocated to health is increasing in all OECD countries, mostly due to new medical technologies and population ageing Source: OECD Health Data 2009, OECD (http://www.oecd.org/health/healthdata).
but cash is tight... Measuring patient outcomes are going to be critical
Current healthcare models are unsustainable delivering efficiency and effectiveness will be major driver Healthcare cannot be delivered in isolation collaboration between Healthcare providers, Governments, patients and industry.
Our relationship with our customers should not be an adversarial one. Governments and health providers face huge challenges and we need to be part of creating a solution... We need to look for ways of aligning both parties value propositions when it comes to particular therapies. ex CEO of AstraZeneca David Brennan
ROLLS-ROYCE POWER BY THE HOUR
I WOULD LIKE A LIFE FREE OF RHEUMATOID ARTHRITIS ( )
What is the problem we are addressing? Business investment is too low and too late Technical and financial risks need to be mitigated The time for financial return is too long for many players Innovation disrupts value chains and business models New partnerships are required to build new supply chains Investment and innovation is required at multiple points Longer term trends not visible to all players Impact and opportunities from emerging technologies & policies Innovation infrastructure complex and inefficient Fragmented and difficult to navigate Sub-national picture changing and less money available overall
Focus on five areas Accelerating the journey between concept and commercialisation Understand the business journey and accelerate it Provide a coherent package of support matched to needs Specific SME package but recognise role of larger companies Promote knowledge exchange Connecting the innovation landscape Turning government action into business opportunity Investing in priority areas based on potential Continuously improving our capability
Medicines and Healthcare strategy Assisted Living Innovation Disease prevention and proactive Platform management of chronic disease Detection and Identification of Earlier and better detection and Infectious Agents Innovation diagnosis of disease leading to marked Platform improvements in patient outcomes Stratified Highly effective Medicine treatments that are tailored to patients needs and either modify the underlying disease or offer potential cures. Regenerative Medicine
Joint Technology Strategy Board and Medical Research Council programme investing 180m over 3 years Deliver growth to the UK life sciences sector through supporting and driving the development of innovative life sciences products and services Supporting both academically- and commercially-led research and development and encouraging partnership between clinicians, academics and industry Moving innovative life sciences products and services quicker and more effectively to commercialisation and ultimately healthcare impact Watch the video on http://ow.ly/bz2da
Catapult Centres 13 Business-focused centres that make world-leading technical capability available to businesses to solve their technical challenges Provides - Access to world-leading technology & expertise Reach into the knowledge base for world-leading science Capability to undertake collaborative R&D projects and contract research with business Strongly business focused with a professional delivery ethos Critical mass of activity creating a focal point Skills development at all levels
Integrating into service delivery is going to be the key challenge
www.innovateuk.org e: zahid.latif@tsb.gov.uk m: +44 7824 599692 tw: zahid_latif_tsb